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1. Introduction 
A small population of cancer stem cells has been identified in a range of haematopoietic and 
solid tumours. These cells retain features of normal stem cells including self-renewal, 
pluripotency and altered gene expression, and might represent the cell of origin of these 
tumours (Dean et al., 2005)(Fallica et al., 2011). The possible eradication of cancer stem cells 
might offer revolutionary advances in the treatment of cancer. However, cancer stem cells 
are rare and are hard to destroy due to the occurrence of high level of multidrug resistance 
(MDR) proteins.  
Tumor cells carrying the MDR phenotype are often associated with the over-expression of 
drug efflux pumps, among which the membrane-bound energy-dependent P-glycoprotein 
(Pgp) is one of the important classes (Marthinet et al., 2000)(Persidis, 1999)(Locke et al., 
2003). The Pgp efflux pump, which belongs to the superfamily of ATP binding cassette 
(ABC) transporters (i.e. ABCB1) (Higgins, 2007) and is encoded by the MDR1 class of genes 
(Gros et al., 1986), actively transports drugs out of the cancer cells. This has caused the 
intracellular drug concentration to be lower than the drug’s efficacy threshold within cancer 
cells (Marthinet et al., 2000), leading to the failure of many forms of chemotherapy (Higgins, 
2007). Gaining a better insight into the mechanisms of cancer stem cell resistance to 
chemotherapy might lead to new therapeutic drug targets and better anti-cancer treatment 
strategies (Dean et al., 2005)(Shervington and Lu, 2008)(Dean, 2009)(Donnenberg and 
Donnenberg, 2005). 
To improve the chemotherapy sensitivity, Pgp inhibitors or MDR modulators have been 
employed, with their effects on MDR reversal studied (Ren and Wei, 2004)(Wang et al., 
2000)(Efferth et al., 2002)(Medeiros et al., 2007)(Meaden et al., 2002). For instance, Ren et al. 
studied the efflux of doxorubicin in human carcinoma cells (Ren and Wei, 2004). But the 
assay conducted by a fluorescence plate reader is not amendable to the study of rare cells 
such as cancer stem cells. Wang et al. developed a method to quantitatively assess Pgp 
inhibitors by flow cytometry (Wang et al., 2000). While this method is widely used to study 
MDR modulation, it does not provide the information of an individual single cell, such as its 
time-dependent drug transport kinetics. In addition, flow cytometry requires a large 
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number (i.e. 100,000) of cells in the starting population to achieve reliable results (Wang et 
al., 2005). This is a challenging requirement especially when only a limited amount of rare 
cells is available.  
Since 2000, the microfluidic technique has been widely used for cell biology applications (Li 
and Li, 2010)(Salieb-Beugelaar et al., 2010). This technique has several advantages for 
conducting cellular assays: (1) the liquid channels or physical microstructures are compatible 
with the micrometer-sized biological cells, and these features make single-cell manipulation, 
or single-cell capture most applicable; (2) the microfluidic devices can be used to analyze a 
small amount of cells, and this aspect is advantageous in bioanalytical applications because 
biological samples are often limited in quantity; (3) this technique has a low reagent 
consumption, and this reduces the assay costs; and (4) the microfluidic technique can integrate 
multiple steps on a single microdevice, including cell sample introduction, fluid control, 
single-cell capture, cell lysis, reagent mixing, and analyte detection.  
In cellular applications, single-cell analysis is preferred to the traditional bulk cellular 
analysis because the former can study cellular heterogeneity and provide information on 
cell-to-cell variations (Sims and Allbritton, 2007)(Li and Li, 2010)(Di Carlo and Lee, 2006). 
Additionally, physicochemical modelling of biological processes also demands data to be 
obtained from a single cell (El-Ali et al., 2006). To date, the single-cell applications using the 
microfluidic devices include intracellular signalling (Li and Li, 2005)(Wheeler et al., 2003)(Li 
et al., 2004), pathogen identification(Zeng et al., 2010), myocyte contraction (Li and Li, 
2005)(Li et al., 2007)(Cheng et al., 2006)(Klauke et al., 2003), drug discovery (Li et al., 
2009)(Li et al., 2007), patch-clamp recording (Chen and Folch, 2006), multidrug resistance (Li 
et al., 2008), cell nanosurgery(Jeffries et al., 2007), electroporation (Ryttsen et al., 2000), 
genetic analysis (Liu et al., 2010)(Hong et al., 2004), protein analysis (Schumann et al., 2008), 
forensic analysis (Liu et al., 2010), cell culture (Peng and Li, 2004), photobleaching of cellular 
fluorescence (Peng and Li, 2005), and so on.  
Recently, we have developed a microfluidic single-cell analysis approach for the study of 
multidrug resistance modulation by real-time monitoring of drug efflux in MDR cancer cells 
(Li et al., 2008). In order to distinguish drug effects of MDR modulators on cancer cells, 
control experiments on untreated cells are needed, but cell heterogeneity in multidrug 
resistance can obscure any positive drug response. To address this issue, we have 
introduced and tested the concept of same-single-cell analysis (SASCA) in which the same 
cell is used as its control in order to compare the effect of MDR modulators on drug efflux 
(Li et al., 2008). In addition to measuring drug efflux, we have also developed a new 
microfluidic approach to study MDR modulation effects of drug candidates by monitoring 
drug accumulation.  
2. Methodology 
This section will briefly introduce the design of the microfluidic chip, followed by the 
procedures for single-cell selection and retention, and the same-single-cell approaches for 
drug efflux and drug accumulation measurements. Finally, the procedures for conventional 
cell assays such as flow cytometry and cytotoxicity tests are listed. 
2.1 Microdevice design and fabrication 
The layout of the glass microfluidic chip is shown in Figure 1a. The chip consists of 3 
channels, 3 reservoirs and 1 chamber containing a cell retention structure. Reservoir 1 is 
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used to introduce cells; reservoir 2 serves as the waste outlet, and reservoir 3 is used for 
reagent delivery. The glass chip was fabricated by Canadian Microelectronic Corporation 
(CMC, Protolyne® Chip) by the standard microfabrication procedure, with a channel depth 
of 20 µm (Manz et al., 1992). An image of the microchip filled with a red food dye is shown 
in Figure 1b. Figure 1c illustrates the 3-dimensional view of the cell retention structure, with 
the retained single cell treated with a flow of drug solution.  
 
 
Fig. 1. Layout of the microfluidic chip. (a) The schematics of the microfluidic chip consisting 
of 3 solution reservoirs and a cell retention structure, with the dimensions (in Ǎm) shown in 
the inset. (b) An image of the microchip filled with a red food dye. A Canadian dime  
(10-cent coin) was placed on the chip for size comparison. (c) A schematic diagram of the  
3-dimensional illustration of the cell retention structure. Reprinted with permission from 
American Chemical Society and Royal Society of Chemistry (Li et al., 2008; Li et al., 2011) 
2.2 Cell culture 
The human wild-type (WT) T-cell leukemic cell line CCRF-CEM (CEM/WT, drug-sensitive) 
was obtained from ATCC. This cell line and its multidrug-resistant vinblastine-selected 
subline (CEM/VLB0.05, drug resistant) were maintained in α-MEM medium supplemented 
with 10% fetal bovine serum and 50 U/mL penicillin, as previously reported (Li et al., 2008). 
2.3 Single-cell selection and retention 
After a cell suspension (~0.1 x 106 cells/mL) was introduced into reservoir 1, the cells flowed 
unidirectionally (from the right to the left) into the microchip. By adjusting the liquid levels 
of reservoirs 1 and 2, a desired cell was adjusted to flow near the entrance of the cell 
retention structure. Then, a liquid flow at the central reagent channel was induced to direct 
the cell into the retention structure. The cell was allowed to settle further for ~ 15 min (900 s) 
before the fluorescence measurement was started. Figure 2 shows the image of a single 
CEM/VLB cell retained in the cell retention structure. The post-retained cell remained alive, 
which was confirmed using a live stain (i.e. fluorescein diacetate), as shown in the inset of 
Figure 2. This approach has been widely used to selectively retain single round-shaped 
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cancer cells and rod-shaped cardiomocytes (Li and Li, 2005; Li and Li, 2006; Li et al., 2007; Li 
et al., 2008; Li et al., 2009; Li et al., 2011)  
 
 
Fig. 2. An optical image of a retained live single CEM/VLB cell, which had been stained by 
fluorescein diacetate (25 ǍM) as shown in the inset. The scale bar is 50 Ǎm. Reprinted with 
permission from American Chemical Society (Li et al., 2008) 
2.4 On-chip drug efflux study on single cells 
As previously described, an optical detection system was employed for simultaneous 
bright-field observation and fluorescence measurement (Li et al., 2009). We measured the 
uptake of the drug daunorubicin (DNR) because it is a substrate of the MDR1 transporter 
(Murthy and Shah, 2007) (Fu and Roufogalis, 2007), and we used the fluorescent method 
since DNR is inherently fluorescent (i.e., ǌem=590 nm, ǌex=470 nm). The chip was shuttled 
back and forth across the detection aperture window so that the signals for the cell or its 
vacant region in the cell medium were obtained in turn. When the cell was inside the 
detection aperture, the cellular fluorescence was measured; whereas the background signal 
was measured when the cell was outside the detection window.  
We have conducted experiments using two methods: different-single-cell analysis (DISCA) 
and same-single-cell analysis (SASCA). In the DISCA method, after one CEM cell was 
selected and retained in the cell retention structure, the cell media in all the reservoirs were 
removed, and then reservoir 3 was filled with DNR (35 ǍM) and left to flow in the 
microchannel for ~1000 s. There was virtually instantaneous replacement of the cell medium 
around the cell by the DNR solution because the space in front of the cell retention structure 
was small. Fluorescent measurement was initiated to observe DNR accumulation in the cell 
(e.g. Cell 1), see Figure 3a. After the accumulation stage, the solutions in all reservoirs were 
replaced by the cell medium (i.e. no DNR) and it was left to flow for ~1800 s. At the same 
time, the cellular fluorescent intensity during drug efflux in the cell medium was measured.  
This procedure was repeated on a second retained cell (e.g. Cell 2). Briefly, it was treated 
with 35 ǍM DNR for ~1000 s, and drug efflux was conducted in cell medium containing a 
MDR inhibitor candidate compound (i.e. VER, IQ or ART) for ~1800 s. The two sets of 
fluorescent intensity curves are depicted in the schematics shown in Figure 3a. Comparison 
of the 2 drug efflux curves (Ed1 vs Ed2) were made subsequently, see Figure 3a inset. 
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Fig. 3. The schematic illustration of DISCA and SASCA for single-cell MDR efflux study.  
(a) In DISCA, two different cycles of accumulation and efflux occur on two different cells, 
namely cell 1 (Ad1 and Ed1), and cell 2 (Ad2 and Ed2). MDR modulation is evaluated by 
comparing the normalized fluorescent intensity of Ed2 and that of Ed1 (different cell control) 
shown in the inset. (b) In SASCA, one and the same cell was used in the 2 cycles of drug 
accumulation (As3, As3’) and efflux (Es3, Es3’). MDR modulation is evaluated by comparing 
the normalized fluorescent intensity of Es3’ with that of Es3 (same cell control) shown in the 
inset. Pd and Pc are the DNR retention percentages in the MDR modulator solution, and in 
the medium alone (control) at efflux time of 1800 s, respectively. These percentages are 
determined by dividing the cell fluorescent intensity at efflux time of 1800 s, with the 
maximum fluorescent intensity before the efflux stage. Reprinted with permission from 
American Chemical Society (Li et al., 2008) 
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In the same-single-cell analysis (SASCA) method, only one retained cell (e.g. Cell 3) was 
used. It was first treated with 35 ǍM DNR for ~1000 s in the drug accumulation stage. 
Thereafter, drug efflux was observed in cell medium alone for ~1800 s (control experiment). 
Then, the same cell was treated a second time with 35 ǍM DNR for ~1000 s, and a second 
drug efflux was observed in cell medium containing a MDR inhibitor candidate compound 
(i.e. VER, IQ or ART) for ~1800 s. The fluorescent intensity curves are depicted in the 
schematics shown in Figure 3b. Comparison of the 2 efflux curves (Es3 vs Es3’) are shown in 
Figure 3b inset. The time needed to complete this procedure was ~115 min, as described in 
our previous report (Li et al., 2008).  
After all drug treatments and cell measurements, trypan blue was used to treat the cell in 
order to evaluate the cell viability. 
2.5 On-chip drug accumulation study on single cells 
In SASCA, only one retained cell (e.g., cell 3) was used. The cell was first treated with DNR 
(8.8 ǍM) in the absence of MDR modulators for ~1400s to test drug accumulation (control 
experiment). Thereafter, the same cell was treated with a DNR solution in the presence of a 
MDR modulator for ~700 s. Since we expect that if the modulator has a positive drug effect, 
there is greater drug accumulation, as displayed by the instant change of the slope depicted 
in Figure 9b.  
2.6 Flow cytometry 
Flow cytometry was performed using a fluorescence-activated cell sorter (FACS) to confirm 
the microfluidic single-cell analysis results, utilizing a previously reported procedure (Wang 
et al., 2000). Briefly, an aliquot (750 ǍL) of the cells (300,000 cells/mL) in the cell culture 
medium was transferred to a plastic tube containing 750 ǍL of incubation medium with 
DNR (35 ǍM). Drug accumulation was conducted at 23 °C for 30 min in the dark. After 
centrifugation (200 g for 5 min) and removal of the supernatant, the cells were re-suspended 
in the cell medium alone (i.e. without DNR) and incubated at 23 °C for an additional 30 min 
(the efflux phase). After removing supernatant, cold HBSS was then added to each tube to 
quench the drug efflux. The cell suspension was transferred to a FACS tube, and was stored 
on ice (for less than 15 min) before analysis. Fluorescent intensity (excitation at 488 nm, 
emission at 570 nm) was measured and displayed as single-parameter histograms, based on 
the acquisition of data from 10,000 cells. The procedure was repeated for the efflux study of 
the cells in the presence of a MDR modulator compound (e.g. VER, IQ and ART). The time 
needed to complete this procedure was ~149 min. as described previously (Li et al., 2008). 
2.7 MTT cytotoxicity assay 
The sensitivities of CEM/WT cells and CEM/VLB cells to the cytotoxic drug DNR were 
determined by the 96-well microtiter plate assay (Jow et al., 2004; Li et al., 2009). To 
summarize, after 1 day of cell seeding in each well, 100 ǍL of test compounds at various 
concentrations were separately introduced in each well. After the cells were further 
incubated for 3 days, 40 ǍL of MTT (5 mg/mL) was added to each well and incubated at  
37 °C for 3 h. Finally, after removing the supernatant and adding DMSO, a microplate 
reader was used to measure the absorbance of each well at 570 nm. The medium without 
test compounds and DMSO alone were used as the negative control and the positive control, 
respectively. All tests were carried out in triplicate. 
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3. Results and discussion 
3.1 Multidrug resistance and drug sensitivity 
We first investigated the different drug responses of the drug-resistant cells (i.e. VLB cells) 
and the wild-type (WT) cells using the MTT cytotoxicity assay. Since VLB cells, but not WT 
cells, have over-expressed Pgp pumps, this discrepancy leads to the difference in the drug 
sensitivities of these two types of CEM cells toward the drug DNR. This difference was 
confirmed by the results of cytotoxicity assay (see Figure 4a). It is estimated that the IC50 
values of DNR (half maximal inhibitory concentration of a drug) for CEM/WT and 
CEM/VLB0.05 are ~80 nM and 15 µM, respectively. Thus, the CEM/VLB cells are ~180 fold 
more resistant to DNR, as compared to the CEM/WT cells. This higher drug resistance of 
the MDR cancer cells is a primary cause of chemotherapy failure, when patients develop 
multidrug resistance. 
3.2 Different-single-cell analysis (DISCA) for drug efflux study in a microchip 
The purpose of this drug efflux study was to test a MDR modulator compound (e.g. 
verapamil or VER) for a possible MDR reversal effect. To achieve this, DNR efflux was 
conducted on a CEM/VLB cell (test cell) in the presence of the modulator compound and 
then on another cell (control cell) in the absence of the compound. Since two cells are 
measured, this analysis is called different-single-cell analysis (DISCA). As described in 
Figure 3a inset, the two efflux curves (Ed1 vs Ed2) obtained from the two different cells (i.e. 
Cell 1 and Cell 2) were compared.  
In the results shown in Figure 5a, we observe the typical drug efflux curves of different 
single drug-resistant cells (CEM/VLB) in various DNR-free solutions such as VER, IQ, and 
the cell medium alone. It was observed that the DNR efflux was initially fast (i.e. 0-500 s). 
Afterwards, the efflux rate slowed down and the cellular fluorescence did not change 
significantly. In addition, less DNR was retained (i.e. 0.2-0.4 or 20-40%) when the efflux was 
conducted in the medium (the efflux-in-medium curve) as compared to the efflux conducted 
in VER (the efflux-in-VER curve). This observation is consistent with the notion that VER 
interferes with the drug efflux process by binding to the Pgp efflux pump, thus resulting in 
more DNR retention (Akiyama et al., 1988; Wang et al., 2000). We also studied the MDR 
effect of another compound, IQ, an ingredient of the traditional Chinese herb licorice (Sung 
and Li, 2004; Cai and Li, 2007). It has been reported that IQ has an anti-tumor effect on 
human gastric cancer (Ma et al., 2001) and leukemia (Li et al., 2009), prostate cancer 
(Kanazawa et al., 2003) and hepatoma (Hsu et al., 2005). However, no obvious inhibition 
effect of IQ on DNR efflux was observed, as the efflux-in-IQ curves were similar to the 
efflux-in-medium curves (see Figure 5a).  
Figure 5a shows the typical curves of DNR efflux among results obtained from multiple 
individual cells. The typical curves represent the cluster of the curves for most cells, as 
opposed to some outliers, see Figure 5b-d. Even in the same cluster, some cellular variations 
were observed. For instance, Figure 5b shows the variations in the cluster of the drug-
resistant cell line (CEM/VLB) and that of the CEM wild-type cell line (CEM/wt). Although 
it can be comfortably inferred that there is a lower drug retention in the CEM/VLB cells 
than in the CEM/WT cells, which was attributed to the overexpressed Pgp pumps in the 
CEM/VLB cells (Higgins, 2007), there are still many variations observed in both clusters. It 
can be observed that some curves of CEM/VLB cells are even close to those of the CEM/WT 
cells, indicating some CEM/VLB cells have more drug retention, which is likely due to less 
Pgp pump activities.  
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Fig. 4. (a) Cytotoxicity assay to show the different drug sensitivities of WT and VLB cells 
toward DNR. (b) A drug accumulation model to describe the higher drug sensitivities (or 
lower drug resistance) of the WT cells, as compared to the VLB cells. KPV and KPW are the 
drug efflux rates in VLB and WT cells, respectively. Reprinted with permission from Royal 
Society of Chemistry(Li et al., 2011) 
b 
a 
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Fig. 5. Modulation of DNR efflux by VER and IQ studied by DISCA in a microchip. (a) The 
typical curves of DNR efflux of CEM/VLB cells in the medium (green, solid symbols), in 50 
ǍM VER (blue, half-filled symbols) and 100 ǍM IQ (red, hollow symbols). (b) Comparison of 
DNR efflux in medium between CEM/WT (red, half-filled symbols) and CEM/VLB (green, 
solid symbols) cells. (c) The effect of VER (red, half-filled symbols in panel) on the DNR efflux 
in CEM/VLB cells. (d) The effect of IQ (red, half-filled symbols in panel) on the DNR efflux 
in CEM/VLB cells. DNR, 35 ǍM. IQ is isoliquiritigenin; VER is verapamil; ART is sodium 
artesunate. Reprinted with permission from American Chemical Society (Li et al., 2008) 
In the cases of drug efflux in VER and in IQ, the MDR reversal effects from these compounds 
cannot be concluded due to the enormous cell variations in the efflux-in-VER cluster, and in 
the efflux-in-IQ cluster, as shown in Figure 5c and 5d, respectively. Although it is well 
known that verapamil (VER) could inhibit the MDR efflux and result in more drug retention 
(Akiyama et al., 1988; Wang et al., 2000), this positive effect of MDR reversal cannot be 
verified in Figure 5c as some efflux-in-VER curves are mixed with the efflux-in-medium 
curves. Since the effect of IQ on MDR reversal is unknown, it is difficult to draw any 
conclusion when we examine Figure 5d. Under this situation, we selected the typical curves 
in each of the 3 cases (shown in Figure 5a) as obtained from many single-cell experiments, 
and tentatively concluded that there is a MDR reversal effect by VER, but not by IQ.  
More single-cell measurements could help the data interpretation and this is one of the 
reasons why conventional FACS requires a large number of cells to achieve reliable results 
(Wang et al., 2005). Nevertheless, it may not be possible to conduct many measurements in 
 
www.intechopen.com
 Cancer Stem Cells - The Cutting Edge 
 
538 
 
 
Fig. 6. Modulation of 50 ǍM verapamil (VER) on DNR efflux of CEM/VLB cells studied by 
SASCA and confirmed by flow cytometry. (a) SASCA method used to study the effect of 
MDR reversal by VER on one and the same CEM/VLB cell. The fluorescence intensities of 
DNR efflux in medium and in VER have been normalized for easy comparison. The insets 
show the cell morphologies before and after the experiment, and after trypan blue treatment. 
(b) Flow cytometry study of the modulation of DNR efflux in CEM/VLB cells by VER. The 
histograms represent the normalized percentage of cell counts plotted against the fluorescent 
intensity expressed as log relative fluorescence. The histograms depict, from left to right, the 
cells without DNR accumulation; the cells with DNR efflux in medium alone; and the cells 
with DNR efflux in VER. DNR, 35 ǍM. Reprinted with permission from American Chemical 
Society (Li et al., 2008) 
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the case of cancer stem cells because of the limited number of cells available. It is because 
one drawback of using DISCA for the MDR efflux study is the inevitable variations in 
cellular properties, such as the MDR activities. In a worse case scenario: if the control cell 
has a lower drug efflux ability (e.g. the highest efflux-in-medium curve in Figure 5c), and 
the test cell has a greater drug efflux ability (e.g. the lowest efflux-in-VER curve in Figure 
5c), the MDR reversal effect of the candidate compound will not be obvious, leading to a 
false negative conclusion. 
3.3 Same-single-cell analysis (SASCA) for drug efflux study in a microfluidic chip 
In order to minimize cellular variations, we conduct the drug efflux study in which the same 
cell is employed as the control cell as well as the test cell. This analysis is thus called same-
single-cell analysis (SASCA). This demands the single cell to be retained long enough 
during the course of the drug efflux study, and is achievable by the cell retention ability of 
the microfluidic chip. The schematic diagram in Figure 3b shows the concept of the SASCA, 
in which 2 cycles of DNR accumulation and efflux steps are conducted on the same single 
cell (e.g Cell 3). As depicted in the inset of Figure 3b, the 2 efflux curves (Es3 vs Es3’) 
obtained from one and the same cell are compared.  
Since the well known effect of MDR reversal of verapamil (VER) cannot be verified by 
DISCA as shown in Figure 5c, we conduct SASCA to verify this effect. Figure 6a shows that 
there is indeed a greater DNR retention when the cell efflux was conducted on the same cell 
in the presence of VER and so it is clear that this well known modulator has reversed the 
DNR efflux process. More SASCA data confirm the same positive result of MDR reversal by 
VER (see Table 1).  
Conventional flow cytometry was also performed to confirm the effect of VER. From Figure 
6b, it is found that the fluorescent intensity (plotted as the x-axis), which indicates the 
intracellular DNR retention, is greater when the drug efflux study is conducted in VER than 
in the cell medium alone, corroborating the microfluidic results. In the flow cytometry 
experiment, during the drug accumulation and efflux procedures (a total of 60 min.) and 
before data collection, no cellular information is collected. But, in SASCA, the full profile of 
the drug transport in the same single cell is recorded even during drug accumulation and 
efflux. In addition, this approach has provided information about the cell morphology, 
which can be seen in the cell images in Figure 6a inset, showing little cell shape changes, and 
non-staining by trypan blue. This data suggested that the cell was still viable, indicating not 
only that the drug-resistant cell was not killed by DNR due to substantial drug efflux, but 
also that the microfluidic method was robust enough for long-term cell measurement. The 
cell images could also be useful in documentation and data interpretation of the MDR 
reversal response. Furthermore, SASCA can comfortably measure one cell selected from a 
small cell population of ~100, in contrast to flow cytometry that requires ~100,000 cells to 
achieve high yield in data collection. A full comparison between flow cytometry and 
SASCA, in terms of experimental time, information content, throughput and automation, 
has been previously reported (Li et al., 2008). 
In a similar manner, the effect of IQ on DNR efflux was studied. It is clear in Figure 7a that 
IQ did not result in a greater DNR retention, and so IQ was ruled out as a MDR modulator 
candidate. Again, the use of the same cell as both the control and test cells in SASCA rules 
out the variations among different cells, and assists in a conclusive data interpretation. More 
experiments on IQ (see Table 1) were conducted, and the same observation (no MDR 
reversal effect by IQ) was achieved. The microchip data are also consistent with the histograms  
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Fig. 7. Effect of IQ on DNR efflux of CEM/VLB cells studied by SASCA and confirmed by 
flow cytometry. (a) Effect of 100 ǍM IQ on MDR reversal studied on one and the same 
CEM/VLB cell. Other conditions are the same as Figure 6a. (b) Flow cytometry study of 
DNR efflux in CEM cells as treated by IQ. The histograms represent, from left to right, the 
CEM/VLB cells without DNR accumulation; the CEM/VLB cells with DNR efflux in IQ  
(100 ǍM); the CEM/VLB cells with efflux in medium alone; and the CEM/WT cells with 
DNR efflux in medium alone. Others conditions for flow cytometry are the same as Figure 
6b. Reprinted with permission from American Chemical Society (Li et al., 2008) 
obtained by conventional flow cytometry (Figure 7b), which shows the CEM/VLB cells have 
a similar DNR retention in IQ as in medium alone, while DNR retention in CEM/WT cells is 
greater than that of the CEM/VLB cells. Similar to the VER experiment, the flow cytometry 
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data did not give more information than SASCA regarding the conclusion of the IQ effect, 
although the histograms provide valuable information about cell distribution, which may be 
important in applications such as the cell-cycle study. 
 
 Verapamil (VER) Isoliquiritigenin (IQ) Artesunate (ART) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Cell 8 Cell 9 Cell 10 
Pd (%) 42.2 28.8 55.7 29.6 45.3 8.8 19.3 35.7 68.8 66.1 
Pc (%) 31.7 17.2 14.4 31.7 40.8 14.4 14.9 10.8 47.6 38.0 
ΔP (%) 10.5 11.6 41.3 -2.1 4.5 -5.6 4.4 24.9 21.2 28.1 
Average  
ΔP (%) 21±17 -1.1±5.1 19.7±10.6 
Rp= Pd / Pc 1.33 1.67 3.87 0.93 1.11 0.61 1.30 3.31 1.45 1.74 
Average Rp 2.3 ±1.4 0.88 ±0.25 1.95 ±0.92 
Gp 3.83±0.86 0.72±0.21 1.39 
Table 1. DNR efflux in CEM/VLB cells as modulated by IQ, VER and ART using SASCA. 
See eqs (1-3) for the definitions of Pd, Pc, ΔP, Rp, and Gp. Reprinted with permission from 
American Chemical Society (Li et al., 2008) 
To quantitatively evaluate the MDR modulations or MDR reversal effects of various drug 
candidates, we define 2 parameters, ΔP and Rp, as follows: 
 ΔP= Pd - Pc (1) 
 Rp= Pd / Pc (2) 
where Pd and Pc are the DNR retention percentages in the MDR modulator solution and in 
the medium alone (control), respectively, see Figure 3b inset.  
In flow cytometry, the fluorescence geometric mean ratio, Gp, is used, as defined in equation 
3 (Medeiros et al., 2007) (Wang et al., 2000). 
 Gp= Gd / Gc (3) 
where Gd and Gc are the fluorescence geometric means in the MDR modulator solution and 
in the medium (control), respectively.  
ΔP gives the DNR retention percentages that the drug candidate can reverse, i.e. the larger 
the ΔP value, the greater is the drug’s MDR reversal. On the other hand, a negative ΔP value 
means that the drug candidate potentiates the drug efflux, resulting in less drug retention. 
Rp is defined for comparison with the data obtained from the flow cytometry method (i.e. 
Gp). The higher is the Rp value above 1, the greater is the MDR inhibition effect; Rp =1 means 
that the drug candidate does not have any MDR modulation effect. If Rp is less than 1, it 
means the drug candidate potentiates the drug efflux. 
Several experiments of 50 ǍM VER by SASCA show that the highest values of ΔP and Rp are 
41.3 and 3.87, respectively (Table 1), indicating that Cell 3 would have the greatest MDR 
reversal effect. This demonstrates the capability of SASCA to evaluate the different cellular 
abilities in response to drug efflux modulation. To compare with the flow cytometry data, 
the averaged values were used, and the average ΔP and Rp for VER (50 ǍM) are 21±17% and 
2.3±1.4 (n=3), respectively (Table 1). The values of ΔP and Rp for IQ (100 ǍM) are similarly 
compared, and they are -1.1±5.1% and 0.88 ±0.25 (n=3), respectively. The Rp values (2.3±1.4 
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and 0.88±0.25) for VER and IQ are similar to the Gp values (3.83±0.86 and 0.72±0.21) 
obtained from flow cytometry data.  
The difference in Rp and Gp values may result from the differences between these two 
measurement methods, and the amount of tested cells, but this does not affect the conclusion 
of MDR modulation in both cases. Although Rp is defined for comparison with the results 
obtained from the flow cytometry method (e.g. Gp), we believe ΔP should be used in 
evaluating the drug candidate’s MDR reversal effect in SASCA since the Pd and Pc values 
have already been normalized into the percentages. Moreover, Rp may be substantially 
affected by the denominator (Pc), especially when the value of Pc is very small. 
The MDR modulation effect of another herbal ingredient, sodium artesunate (ART) was also 
studied. ART, which was derived from ‘Qinghao’, was first discovered as an anti-malarial 
drug (Dai and Chen, 1999), and subsequently found to have anti-cancer property (Wang et 
al., 2002). Figure 8a shows that the DNR efflux is reversed in the presence of ART, as 
compared with the efflux in the cell medium (medium 1, before ART). In order to confirm 
this finding, a second efflux step in the medium (medium 2) was conducted after the MDR 
reversal by ART. It was found that the efflux-in-medium curve in the second case was 
consistent with that in the first, thus confirming the finding that the MDR modulation effect 
of ART was genuine. More same-single-cell experiments also confirmed the effect of ART 
(300 Ǎg/mL) on MDR efflux, as shown by the mean values of ΔP and Rp, which are 
19.7±10.6% and 1.95 ±0.92, respectively (see Table 1). It has been reported that ART (60 
Ǎg/mL) significantly increased DNR accumulation in the MRP1-expressing cells, but not  in 
the MDR1-expressing CEM cell line (Efferth et al., 2002). We discovered that when ART was 
more concentrated than 200 Ǎg/mL, it produced a beneficial MDR inhibition effect, 
consistent with the flow cytometry data (Figure 8b). No inhibition effect on MDR efflux was 
observed in lower concentrations of ART (100 Ǎg/mL). 
3.4 Simpler, faster, and more reliable method of microfluidic same-single-cell analysis 
The study of multidrug resistance based on drug efflux is fairly complicated because it 
involves multiple cycles of drug uptake and drug efflux, and each assay is time-consuming. 
In addition, the time period between the two drug efflux processes (i.e. test and control or te1 
+ tr + ta2,), as shown in Figure 9a, might cause slight differences in the cellular health status 
or Pgp activities. Although multiple controls can be adapted to confirm cell status as we 
reported previously (Li et al., 2008), it complicates the assay process. To overcome these 
problems and work toward an ‘identical’ control, we are reporting a new microfluidic 
SASCA approach for the study of MDR modulation by monitoring drug accumulation in 
single cells. Based on the same concept of SASCA, this new approach is simpler, faster and 
more reliable for MDR study by investigating drug accumulation, instead of drug efflux. 
As illustrated in the Figure 9b inset, during the drug accumulation stage in the presence of 
DNR, the drug uptake process and the drug efflux process by Pgp pumps occur 
simultaneously. In contrast to WT cells, more DNR is pumped out of MDR cells, leading to 
low drug accumulation in these cells. But when the MDR cells’ Pgp pumps are inhibited by 
a MDR modulator compound (e.g., VER), less DNR is pumped out, leading to a higher 
intracellular drug accumulation (i.e., the MDR reversal effect). Therefore, we can choose to  
measure DNR accumulation in order to determine whether a compound has the MDR 
reversal effect, instead of the time-consuming measurement of the DNR efflux process (Li et 
al., 2008). We call this approach SASCA-A to differentiate it from the previous approach of 
same-single-cell analysis, termed as SASCA (Li et al., 2008).  
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Fig. 8. Modulation of ART on DNR efflux of CEM/VLB cells as studied by SASCA (a) and 
confirmed by flow cytometry (b). (a) Effect of MDR reversal by ART (300 Ǎg/mL) studied by 
SASCA on one and the same CEM/VLB cell in a microfluidic chip. A second efflux in 
medium (Medium 2) confirmed that the effect of 300 Ǎg/mL ART (ART300) was genuine 
after the first efflux in medium (Medium 1). Both efflux steps in medium alone were used as 
control experiments. Other conditions are the same as Figure 6a. In (b), flow cytometry 
revealed the effect of artesunate (100, 200, 300 Ǎg/mL) on DNR efflux in CEM/VLB cells. 
The histograms from the medium alone and 100 Ǎg/mL ART are offset vertically and shown 
in the inset to provide greater detail. Others conditions for flow cytometry are the same as 
Figure 6b. Reprinted with permission from American Chemical Society (Li et al., 2008) 
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Fig. 9. The schematic illustration of two SASCA approaches for single-cell multidrug 
resistance study (a) by a microfluidic method measuring drug efflux process and (b) by a 
new approach via investigating drug accumulation. The inset depicts a mathematical model 
to describe the kinetics of drug accumulation, with Kd and Kp representing the drug uptake 
rate and drug efflux rate, respectively. Reprinted with permission from Royal Society of 
Chemistry (Li et al., 2011) 
In the SASCA-A experiment, we used a lower concentration of DNR (e.g., 8.8 µM) to 
minimize cytotoxic effect on cells. It was found that the accumulation was initially fast, then  
it reached a relatively ‘steady’ state (after 470 s as seen in Curve 3 in Figure 10). This showed 
a balance of the drug uptake and efflux processes, as previously observed (Ren and Wei, 
2004)(Wang et al., 2000). It was only when the DNR concentration was low enough and the 
accumulation was relatively slow that the ‘steady’ accumulation stage was obvious. During 
this ‘steady’ state, if an MDR inhibitor-containing DNR solution is applied (see Figure 9b 
and 10), the MDR modulation will tip the balance at this ‘steady’ state, and the drug 
accumulation rate will increase instantly. This is shown by the abrupt slope change in the 
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curve (see Figure 9b and 10). This provides us a simple and fast means to monitor MDR 
modulation using this SASCA-A method, without a long waiting period which is inevitable 
in the previous SASCA method (Li et al., 2008).  
Figure 10 shows an obvious slope transition in the drug accumulation curve when a VER–
containing DNR solution was applied to the cell at 1370 s (Curve 3). The slope transition 
indicates a MDR reversal effect in which there is a faster DNR accumulation as compared to 
the ‘steady’ state before VER was added. Thus, the MDR reversal effect of VER can easily be 
determined by the new approach of microfluidic SASCA-A. However, when an IQ-
containing DNR solution was added, no obvious slope transition was observed (see Curve 2). 
This was similar to the negative control when only DNR (without MDR inhibitors) was 
applied (at 1562 s in Curve 1), which indicated that IQ did not have MDR reversal effect on 
CEM cells. More SASCA data confirmed the different reversal effects from VER and IQ, as 
listed in Table 2. The SASCA-A method can readily conclude the effects of not only VER but 
also IQ, directly on the same single cell, by minimizing the cellular variations among 
different single cells. The effects of VER and IQ were further confirmed by the conventional 
technique of flow cytometry (data not shown).  
 
 
Fig. 10. MDR modulations from VER and IQ in CEM/VLB cells by the new approach of the 
same-single-cell analysis of drug accumulation (SASCA-A). DNR solutions (8.8 ǍM) in the 
presence of VER (50 ǍM) and IQ (100 ǍM) were applied to cells at 1370 s (Curve 3) and at 
1402 s (Curve 2), respectively. In Curve 1, 8.8 ǍM DNR in the absence of MDR modulators 
was added at 1562 s as a negative control. The relative fluorescence intensities have been 
offset for clarity. The inset shows the images of the cells before and after the VER 
experiment. Reprinted with permission from Royal Society of Chemistry (Li et al., 2011) 
In a similar manner, this microfluidic SASCA-A approach was applied to study the effect of 
PSC 833 on MDR modulation. PSC 833 (Valspodar, a non-immunosuppressive cyclosporin 
D derivative) is a less toxic Pgp inhibitor (Thomas and Coley, 2003). As shown in Figure 11, 
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a slope transition was observed as soon as 3 µM PSC 833 in a DNR solution was applied to 
the cell at 1458 s (see Curve 2), indicating a faster drug accumulation due to the inhibition of 
Pgp pumps by PSC 833. More same-single-cell experiments also confirmed the MDR 
reversal effect of PSC 833 on drug accumulation in MDR cancer cells. This is consistent with 
previous reports that PSC 833 can inhibit Pgp pumps and improve the chemotherapy 
response (Warmann et al., 2002). As a control, when the same PSC 833 solution was applied 
to CEM/WT cells (at 1368 s on Curve 3), no obvious slope transition occurred and the drug 
accumulation in the cells still increased linearly with the same slope as before. This implied  
 
 
Fig. 11. MDR modulations from PSC 833 in CEM cells by the microfluidic approach of 
SASCA-A. DNR solutions (8.8 ǍM) in the presence and absence of 3.0 ǍM PSC 833 were 
applied to CEM/VLB cells at 1458 s in Curve 2 and at 1562 s in Curve 1, respectively. In 
Curve 3, a DNR solution (8.8 ǍM) in the presence of 3.0 ǍM PSC 833 was applied to a 
CEM/WT cell at 1465 s. The relative fluorescence intensities have been offset for easy 
comparison. The different segments of Curve 2 and Curve 3 have been linearly fitted and 
shown as straight lines along the curves. KAc and KAd are the slopes of fitted lines before and 
after applying drug modulators in CEM/VLB cells, and Kwt is the slope of the fitted line in 
CEM/WT cells. Reprinted with permission from Royal Society of Chemistry (Li et al., 2011) 
that the MDR modulator did not have any reversal effect on the drug accumulation in 
CEM/WT cells, as were similarly observed in previous reports (Hu et al., 1990). During the 
drug accumulation in WT cells as seen in Curve 3, no obvious ‘steady’ state was observed, 
and yet the accumulation rate was fairly constant after 838 s. As time went on, there was an 
increasingly greater deviation in the amount of drug accumulation between WT cells (Curve 
3) and drug-resistant cells (Curve 1). Accordingly, the SASCA-A approach cannot only 
readily identify MDR modulators, but can also clearly distinguish CEM sensitive cells from 
MDR cells. This method might be used to distinguish MDR cells or cancer stem cells from a 
population of cells. 
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To quantitatively evaluate the MDR modulations or MDR reversal effects of various drug 
candidates using the SASCA-A method, two parameters have been defined, namely, the 
ratio of drug accumulation rates (denoted as RA), and the MDR reversal percentage (ΔRA%), 
as follows: 
 ADA
AC
K
R
K
=  (4) 
 % AD ACA
wt
K K
R
K
−Δ =  (5) 
where KAd and KAc are the slopes of the linearly fitted lines on the drug accumulation curves 
of the CEM/VLB cells in the presence of drug plus MDR modulators (modulators + DNR) 
and in the absence of MDR modulators (DNR only), respectively; Kwt is the slope of the 
fitted line on the curve of the CEM/WT cell.  
In this way, RA indicates how much a MDR modulator affects the drug accumulation in a 
MDR cell. Therefore, the greater RA is, the stronger the reversal effect of MDR modulators 
will be. Since RA does not reveal how close the MDR reversal of the VLB cell is to the drug 
accumulations in the WT cell, we have also defined ΔRA%. Based on these two equations, 
the values of RA and ΔRA% were calculated and listed in Table 2. Both average values of RA 
and ΔRA% confirm the positive MDR reversal effects by VER and PSC 833, but not by IQ. 
The average values of ΔRA% of VER, IQ, and PSC 833 are 57.4, -0.1, and 29.5, respectively, 
showing that 50 µM VER has a greater MDR reversal effect as compared to 3 µM PSC 833. 
From Table 2, we also found that different cells responded to MDR modulators differently. 
The values of ΔRA% of VER on cell 1, 2, and 3 are 67.0%, 52.7%, and 52.3%, respectively. Cell 
1 shows the highest response on the MDR reversal effect from VER among the cells tested in 
this work. This kind of cellular heterogeneity in MDR modulation was also observed in 
previous reports (Li et al., 2008).  
 
 verapamil (VER) isoliquiritigenin (IQ) PSC 833 (PSC) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Cell 8 Cell 9 
RA 7.2 9.1 27.5 0.9 0.9 1.1 4.2 16.5 4.5 
Average RA 14.6±11.0 1.0±0.1 8.4±7.0 
Kwt 0.0081±0.0005 
ΔRA% 67.0 52.7 52.3 -0.7 -0.6 1.0 27.9 33.8 26.9 
Average ΔRA%  57.4±8.4   -0.1±1.0   29.5±3.7  
Table 2. DNR accumulation in CEM/VLB cells as modulated by VER (50 µM), IQ (100 µM), 
and PSC833 (3 µM) using SASCA-A. For notations, see Figure 11 and eqn (4-5). Reprinted 
with permission from Royal Society of Chemistry (Li et al., 2011) 
3.5 Dynamics of drug accumulation in MDR cells 
We believe the understanding of drug accumulation dynamics in MDR cells will benefit the 
design and exploitation of novel MDR inhibitors. Therefore, we have also developed a 
mathematical model to describe the process of drug accumulation. As shown in the Figure 
9b inset, the drug accumulation rate is determined by the drug uptake process as well as the 
drug efflux process by Pgp pumps. Assuming that the drug uptake is by passive diffusion 
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and the drug efflux is controlled by an enzymatic process based on the Michaelis-Menten 
equation ( Peng and Li, 2004, Agarwal et al., 2007), we developed the following equation to 
describe the drug accumulation dynamics (See the reference (Li et al., 2011) for the derivation). 
  
(6)
 
where C is the concentration of DNR; t is the time; Cout and Cin are the extracellular and 
intracellular DNR concentrations, respectively; D is the diffusion coefficient; A is the cell 
surface area; V is the cell volume; x is the cell membrane thickness; and vmax and Km are the 
maximum rate and the Michaelis-Menten constant, respectively, in the Michaelis-Menten 
equation for the drug efflux process.  
From this equation, we find the initial drug accumulation is dominated by the drug uptake 
process when there is a large gradient (Cout-Cin)/x between extracellular and intracellular 
DNR concentrations. Due to this large gradient, the initial drug accumulation rate is very 
fast, as shown by Curve 1 in Figure 11 (before 100 s). When the gradient across the cell 
membrane becomes smaller, the drug uptake becomes slower (see part (a) of eqn (6)). The 
drug efflux process begins to play a significant role in the dynamics of the drug 
accumulation process (see part (b) in eqn (6)). When the drug uptake rate is close to the drug 
efflux rate, that is, part (a) is similar to part (b) in eqn (6), it will reach a ‘steady’ state, as 
shown by the part of curve 1 (Figure 11) after 450 s. However, when a MDR modulator is 
applied, it will bind to Pgp, and inhibit the drug efflux pump, leading to a decrease of the 
maximum efflux rate (vmax) shown in eqn (6). Accordingly, the drug uptake process again 
dominates, as shown by the upward slope transition in the drug accumulation (see Curve 2 
in Figure 11). Therefore, the data obtained from the SASCA-A method can help us to 
understand the drug accumulation in multidrug resistance. Further work about the 
simulation of the various processes involved in multidrug resistance is underway. A note of 
caution: the cellular kinetic response can be misinterpreted by averaging the data obtained 
from bulk analysis (Di Carlo and Lee, 2006).  
4. Conclusion 
The same-single-cell analysis conducted in a microfluidic chip has demonstrated the 
advantages in identifying MDR modulators, and in quantifying the MDR reversal effect of 
drug candidates during the drug efflux stage based on the defined parameter of ΔP. It has 
been demonstrated that SASCA is superior to DISCA by ruling out the difference in MDR 
activities among different cells and presenting a conclusive result about the effect of MDR 
modulators by using the same cell as both the test and the control cell.  
SASCA is also compared with the conventional flow cytometry method in the study of MDR 
modulator candidates. The time needed to conduct SASCA is shorter than flow cytometry, 
and the microfluidic operation will become less tedious after automation in cell manipulation 
and fluorescent data collection. Moreover, the microfluidic SASCA method can provide 
time-dependent drug transport kinetics and cell morphological information, and only a 
small amount of cells are needed to confirm the findings. Therefore, this technique may 
have significant potential for investigating drug resistance in minor cell subpopulations (e.g. 
cancer stem cells) that may be the key determinant of clinical response to chemotherapy.  
max  out in in
m in
c c v cdc A
D
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In addition, this microchip-based method, SASCA, is envisioned for clinical use as a 
companion diagnostics method, e.g. to check the MDR profile and drug responses so as to 
identify personalized drugs before patient treatment starts. This is an important step in 
determining the drug efficacy in individual patients. This approach will be even more 
robust if multiple parallel channels/structures are used to improve throughput (Di Carlo et 
al., 2006)(Faley et al., 2008). Moreover, the time-dependent data from SASCA can help us to 
understand the kinetics and mechanism of drug accumulation or efflux in MDR cancer cells. 
Compared to the SASCA approach for the MDR modulation study in the drug efflux stage 
(Li et al., 2008), the new method—microfluidic SASCA-A has four significant advantages. (1) 
It is simpler; as illustrated in Figure 9, it does not need multiple drug accumulation and 
drug efflux stages as used in the previous SASCA method. (2) It is faster; a typical SASCA-A 
experiment could be finished within 2200 s (ta1’+ta2’ in Figure 9b). That is about one fourth of 
the time used in the previous SASCA experiments (ta1+te1+tr+ta2+te2). As a more efficient 
assay method, this improves the throughput of MDR assays. (3) SASCA-A provides more 
‘identical’ and reliable controls. Here, the previous SASCA has two limitations. First, the 
previous SASCA needs a longer measurement time. Long term exposure to cytotoxic drugs 
is detrimental to cells because the cell status or health conditions may change over time. To 
make sure the cell still have similar conditions, a second control experiment could be 
conducted, as we reported previously in testing ART (Li et al., 2008). Nevertheless, this dual 
control experiment makes the assay more complicated, and consumes more time. Secondly, 
there is a time interval of ~ 3700 s (te1+tr+ta1 in Figure 9a) between the two efflux stages in 
the previous SASCA approach; that is, the two efflux stages start at different life time points 
of a cell. Even though these points refer to the same cell, they are still not true identical 
controls. In terms of Pgp, which has been the most studied drug efflux protein (Perez-
Tomas, 2006) (Gillet et al., 2007)(Davey et al., 1996), research shows that after the drug 
molecules bind to the transmembrane domains of the protein, the ATP-binding domains are 
activated and the drug molecules are then transported out of the cell by a major 
conformational change of Pgp via an enzymatic process (Perez-Tomas, 2006)(Higgins, 2007). 
During this time interval of ~ 1 h, any change in the enzymatic process might cause changes 
in the drug efflux abilities of Pgp pumps.  
Considering these two limitations from the previous SASCA method, SASCA-A takes less 
time and it compares the time points just before MDR modulator tests. Therefore, SASCA-A 
has a more ‘identical’ and reliable control than SASCA. (4) SASCA-A may be more accurate 
in representing the patient’s cells during cancer chemotherapy in which the cancer patient is 
exposed to a continuous drug infusion for a defined period of time.  
In conclusion, it is found that it is less time-consuming to evaluate MDR reversal effects of 
drug candidates by studying the drug accumulation stage than the efflux stage using 
SASCA. Having said that, in the investigation of MDR dynamics, it might be less complex to 
study the drug efflux stage than to study the drug accumulation stage. It is because in the 
former case, only the drug efflux process is involved, but in the latter case, both drug uptake 
and efflux processes should be accounted for. Therefore, the combination of studying both 
stages will likely provide insight for the overall mechanism of multidrug resistance, 
especially when associated with cancer stem cells. 
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